20 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Kurian, Medical Oncologist in Stanford, CA?
Castle Connolly Top Doctor
Castle Connolly Top Doctors are doctor-nominated and selected by a physician-led research team.
What are Areas of Expertise for Dr. Kurian?
Dr. Allison Kurian, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Kurian empowers patients to confidently navigate their health journey, specializing in Breast Cancer Risk Assessment, Cancer Genetics, Gynecologic Cancers, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Kurian is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Kurian go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine CA | Stanford University School of Medicine,Stanford, Ca, United States
Residency: Massachusetts General Hospital
Medical School: Harvard Medical School, Boston, Massachusetts
Is Dr. Kurian board certified as a Medical Oncologist?
Yes, Dr. Allison Kurian, MD is board certified by the American Board of Internal Medicine since 2005
What languages does Dr. Kurian speak?
Dr. Kurian and their clinical team can communicate with patients in the following languages:
- English
- French
- Spanish
What conditions does a Medical Oncologist like Dr. Kurian typically treat?
As a Medical Oncologist, Dr. Kurian diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Kurian. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Breast Cancer
- Female Breast Cancer
- Malignant Breast Tumor
- Breast Carcinoma
- Mammary cancer
- Breast carcinoma
- Breast tumor
ICD-10 Codes:
- C50919: Malignant neoplasm of unspecified site of unspecified female breast
- C50912: Malignant neoplasm of unspecified site of left female breast
- C50911: Malignant neoplasm of unspecified site of right female breast
Also known as:
- Family History of Breast Cancer
- Breast Cancer
- Family History
- Hereditary breast cancer risk
- Genetic predisposition to breast cancer
- Breast cancer in the family
ICD-10 Codes:
- Z803: Family history of malignant neoplasm of breast
Also known as:
- Genetic Counseling
- Genetic risk assessment
- Hereditary counseling
- DNA counseling
ICD-10 Codes:
- Z7183: Encounter for nonprocreative genetic counseling
What procedures does a Medical Oncologist like Dr. Kurian typically perform?
As a Medical Oncologist, procedures performed by Dr. Allison Kurian may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Kurian's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Kurian accept my insurance?
Dr. Kurian accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Kurian accept in Stanford, CA?
Dr. Kurian in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Blue Shield of California
Centene Corporation
Cigna Group
CVS Health (formerly Aetna)
Medicaid
Medicare
Other Provider Networks
State of California
UnitedHealth Group
Valley Health Plan
View All Insurances
Where is Dr. Kurian's office located?
What hospitals are Dr. Kurian affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Kurian has admitting privileges at the following hospitals:
Recognitions
Awards
Translational Research Award – California Breast Cancer Research Program, 2010
Physician Faculty Scholars Award – Robert Wood Johnson Foundation, 2008
Young Investigator Award – American Society of Clinical Oncology, 2005
Fellowship Award – Cancer Research and Prevention Foundation, 2005
Fellowship Award – California Breast Cancer Research Program, 2005
Merit Award – American Society of Clinical Oncology, 2004
Cornelius L. Hopper Research Abstract Award – California Breast Cancer Research Program, 2007
BIRCWH K12 Scholar Award – National Institutes of Health, 2006
Top 12 publications funded by the Epidemiology and Genomics Research, 2011
Suzanne Pride Bryan Award for Breast Cancer Research – Stanford University Cancer Institute, 2013
New Clinical Investigator Award – Stanford University Cancer Institute, 2011
Jan Weimer Faculty Chair for Breast Oncology – Stanford University Cancer Institute, 2008
Publications
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment.
Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers, 2012
Oncoshare: lessons learned from building an integrated multi, 2012
Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations, 2011
Survival Alysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers, 2010
Second Primary Breast Cancer Occurrence According to Hormone Receptor Status, 2009
Performance of BRCA1/2 mutation prediction models in Asian Americans, 2008
A cost-effectiveness alysis of adjuvant trastuzumab regimens in early HER2, 2007
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonce imaging, 2006
Obesity and Mortality After Breast Cancer by Race, 2014
A young woman with bilateral breast cancer, 2013
Information technology interventions to improve cancer care, 2013
A Population-Based Observatiol Study of First, 2013
Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover, 2012
Single Cell Profiling of Circulating Tumor Cells, 2012
Accuracy of BRCA1/2 Mutation Prediction Models, 2012
In reply to Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations, 2012
A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer, 2011
High-resolution melting alysis for rapid screening of BRCA2 founder mutations in Southern Chinese, 2010
Genetic/familial high-risk assessment: breast and ovarian., 2010
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California, 2010
In reply to 'Tailoring BRCRAPRO to Asian Americans?' by S. Chen et al, 2009
The Decline in Breast Cancer Incidence: Real or Imagiry?, 2009
Magnetic resonce galactography, 2008
CDH1 truncating mutations in the E-cadherin gene, 2007
Ductal pattern enhancement on magnetic resonce imaging of the breast due to ductal lavage, 2007
Breast magnetic resonce image screening, 2004
Breast cancer treatment across health care systems, 2014
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment.
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2013
Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers, 2012
Oncoshare: lessons learned from building an integrated multi, 2012
Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations, 2011
Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers, 2010
Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups, 2010
Second Primary Breast Cancer Occurrence According to Hormone Receptor Status, 2009
Performance of BRCA1/2 mutation prediction models in Asian Americans, 2008
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2, 2007
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging, 2006
Histologic types of epithelial ovarian cancer: have they different risk factors?, 2005
Obesity and Mortality After Breast Cancer by Race, 2014
Response., 2014
The California Breast Cancer Survivorship Consortium (CBCSC), 2013
A young woman with bilateral breast cancer, 2013
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers, 2013
The California Breast Density Information Group
Information technology interventions to improve cancer care, 2013
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk, 2013
Impact of breast cancer subtypes on three-year survival among adolescent and young adult women, 2013
A Population-Based Observational Study of First, 2013
Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients, 2012
Identification of BRCA1, 2012
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations, 2012
A Simulation Model to Predict the Impact of Prophylactic Surgery, 2012
Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover, 2012
Single Cell Profiling of Circulating Tumor Cells, 2012
Patient, Hospital, and Neighborhood Factors Associated with Treatment of Early, 2012
Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in, 2012
In reply to Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations, 2012
Genetic Polymorphisms as Predictors of Breast Cancer Risk, 2012
Occurrence of breast cancer subtypes in adolescent and young adult women, 2012
A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer, 2011
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry, 2011
Hereditary cancer: counseling women at risk, 2011
High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese, 2010
Genetic/familial high-risk assessment: breast and ovarian., 2010
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California, 2010
BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications, 2010
Performance of Prediction Models for BRCA Mutation Carriage in Three Racial, 2009
In reply to 'Tailoring BRCRAPRO to Asian Americans?' by S. Chen et al, 2009
The Decline in Breast Cancer Incidence: Real or Imaginary?, 2009
Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease., 2009
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers, 2008
Magnetic resonance galactography, 2008
A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature, 2007
CDH1 truncating mutations in the E-cadherin gene, 2007
Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage, 2007
Biomedical terahertz imaging with a quantum cascade laser, 2006
Opinions of women with high inherited breast cancer risk about prophylactic mastectomy, 2005
Ductal lavage of fluid-yielding and non, 2005
Breast magnetic resonance image screening, 2004
What is Dr. Kurian's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Kurian's National Provider Identifier (NPI) number is 1144385758.
What common questions do patients ask about Dr. Kurian?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Kurian